Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks I'd Never Touch

By Maxx Chatsko - Mar 6, 2017 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Northern Dynasty Minerals, Resolute Energy, and Editas Medicine are scorching-hot stocks, but I won't be going anywhere near them.

The stock market seems to be touching new all-time highs on a consistent basis -- and it may not be all fluff. Many companies and industries have reported impressive full-year 2016 earnings, and the economy as a whole appears to be continuing its expansion. Investors are optimistic that the good times will last for at least a little while longer. 

A rising tide may lift all ships, but there's no doubting that some stocks are hotter than others. Investors in Northern Dynasty Minerals (NAK 6.02%), Resolute Energy (NYSE: REN), and Editas Medicine (EDIT -0.22%) have enjoyed quite a run recently. But while the three stocks have had success recently, I have absolutely no interest in adding them to my portfolio. Here's why you may want to consider keeping your distance, too.

Refusing money

Image source: Getty Images

World's largest headache?

Northern Dynasty Minerals may have given up a good chunk of its eye-popping gains in the last month, but the stock is still up nearly 320% in the last year. Investors thought that a Trump presidency would result in deregulation, specifically for strict environmental laws, which would grease the wheels for getting the company's Pebble Project -- one of the largest undeveloped reserves of gold and copper in the world -- off the ground. Management wasted little time reassuring the market that its prospects were trending in the right direction. 

In late January the company issued a press release stating that it had the backing of the new administration and told investors to expect a solution to the previously derailed permitting process with the U.S. Environmental Protection Agency within 100 days. A new partner would be found to help develop Pebble by the end of the year, too. 

But the details haven't quite supported the initial euphoria.

NAK Chart

NAK data by YCharts.

For instance, even if the EPA agrees to traverse the permitting process with Northern Dynasty Minerals, it could take up to four years and $150 million to complete -- and that's if everything goes smoothly. Then, the company has to spend, presumably, hundreds of millions to billions of dollars to develop the Pebble Project before the first ore can be extracted and sold. One big problem: The concentration of gold in ore found during the company's own exploratory drilling is at least half of that found in other American gold mines, which are also among the world's most expensive.

In other words, everything has to go perfectly (and then some) for Northern Dynasty Minerals to make investors money on a consistent basis. I'm not risking it. 

A premium valuation could squeeze investors

Resolute Energy stock was trading at $32 per share when I first told investors that they should consider locking in gains. It has gained another 46% since then thanks to a continued stream of favorable developments. The company exited 2016 producing over 20,000 barrels of oil equivalent per day (BOE/D), mostly from its high-growth assets in the Permian Basin, and expects its full-year 2017 average production to be up to 40% higher. It also agreed to a new $150 million credit facility and reported an 82% increase in proved reserves, which now stand at 60.3 million BOE. 

REN Chart

REN data by YCharts.

Operations are certainly improving and the balance sheet is becoming healthier, but I still won't be going near the stock. Why not? Resolute Energy owns a market cap near its all-time high set in 2011, but it's still far from achieving the same financial performance. Consider that full-year 2016 revenue will easily be less than half of the all-time high watermark of $350 million set in 2013. And although EPS is improving each quarter, the company is still far from profitability. Even without accounting for transition-related expenses, its gross profit in the third quarter of 2016 was half of the quarterly average from 2013. 

Put another way, while investors are rewarding Resolute Energy stock for rapidly improving operations, there's a long way for the company to go before it really earns its current valuation. That hints that the stock may struggle to find sustainable gains in the future, or may even give up some of its recent gains.

Undisputed winner of gene editing legal spat

Editas Medicine stock is down roughly 19% in the past year, but it has been on fire since last November. The biggest catalyst, of course, was the recent U.S. Patent and Trademark Office decision that allowed the company's licensed intellectual property to stand. It swiped away the legal uncertainty hanging over the stock regarding the genome editing tool known as CRISPR, which is the centerpiece of the company's gene editing technology platform. The details of the decision also meant the company wouldn't have to go through the potentially messy process of licensing additional patents, which could have come at a substantial cost both upfront and in future milestone and royalty payments.

EDIT Chart

EDIT data by YCharts.

The decision means investors can now focus on more familiar biopharma risks, such as the uncertainty of clinical trials. However, investors are only at the beginning of a long R&D process. In fact, Editas Medicine won't begin its first clinical trial until later this year at the earliest. 

It's not all bad news. The company ended September with $200 million in cash on hand. That can go quickly, especially for a company without revenue, but Editas Medicine has only partnered one of its seven therapeutic programs. Its two peers, Intellia Therapeutics and CRISPR Therapeutics, have partnered three and five programs, respectively. It seems that management -- or potential partners -- waited for the patent issue to be cleared before engaging in collaborative talks. With the worst now over, and the company's intellectual property position stronger than ever, management should be able to cash in on its gamble and pad its cash position even further with new partnerships and upfront payments.

Therefore, my decision to stay away from Editas Medicine isn't based on my concerns with the company's operations, but rather due to the simple fact that the company is still in the earliest stages of development with a technology that has yet to be proven in humans. Until the range of possible outcomes is narrowed and more certainty emerges for the pipeline, I won't be touching the stock.

What does it mean for investors?

A rising stock market can mask the potential red flags of a stock. Despite recent gains by Northern Dynasty Minerals, Resolute Energy, and Editas Medicine, investors that dig deeper into the details will discover solid reasons to think twice before starting a new position. I'll be looking elsewhere for stocks to add to my portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Northern Dynasty Minerals Ltd. Stock Quote
Northern Dynasty Minerals Ltd.
$0.28 (6.02%) $0.02
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$13.47 (-0.22%) $0.03
Intellia Therapeutics Stock Quote
Intellia Therapeutics
$53.41 (5.22%) $2.65
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$66.96 (2.78%) $1.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.